
Dolby Laboratories (DLB) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
369.6M
Gross Profit
333.7M
90.30%
Operating Income
112.0M
30.30%
Net Income
92.2M
24.96%
EPS (Diluted)
$0.94
Balance Sheet Metrics
Total Assets
3.2B
Total Liabilities
646.0M
Shareholders Equity
2.6B
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
129.4M
Free Cash Flow
168.0M
Revenue & Profitability Trend
Dolby Laboratories Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.3B | 1.3B | 1.3B | 1.3B | 1.2B |
Cost of Goods Sold | 140.5M | 152.6M | 141.4M | 130.0M | 146.5M |
Gross Profit | 1.1B | 1.1B | 1.1B | 1.2B | 1.0B |
Gross Margin % | 89.0% | 88.3% | 88.7% | 89.9% | 87.4% |
Operating Expenses | |||||
Research & Development | 263.7M | 271.5M | 261.2M | 253.6M | 239.0M |
Selling, General & Administrative | 604.9M | 612.8M | 634.0M | 556.8M | 555.7M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 868.5M | 884.4M | 895.2M | 810.5M | 794.7M |
Operating Income | 264.7M | 262.8M | 217.2M | 340.8M | 220.6M |
Operating Margin % | 20.8% | 20.2% | 17.3% | 26.6% | 19.0% |
Non-Operating Items | |||||
Interest Income | - | - | 6.6M | 3.5M | 12.7M |
Interest Expense | - | - | 394.0K | 479.0K | 186.0K |
Other Non-Operating Income | 13.7M | -40.8M | -8.1M | 10.7M | 6.6M |
Pre-tax Income | 312.5M | 250.1M | 215.3M | 354.5M | 239.7M |
Income Tax | 48.2M | 48.4M | 31.4M | 36.7M | 8.1M |
Effective Tax Rate % | 15.4% | 19.4% | 14.6% | 10.3% | 3.4% |
Net Income | 264.3M | 201.6M | 183.9M | 317.8M | 231.6M |
Net Margin % | 20.8% | 15.5% | 14.7% | 24.8% | 19.9% |
Key Metrics | |||||
EBITDA | 358.4M | 405.4M | 331.5M | 449.9M | 353.6M |
EPS (Basic) | $2.74 | $2.10 | $1.84 | $3.07 | $2.30 |
EPS (Diluted) | $2.69 | $2.05 | $1.81 | $2.97 | $2.25 |
Basic Shares Outstanding | 95544000 | 95771000 | 99990000 | 101190000 | 100564000 |
Diluted Shares Outstanding | 95544000 | 95771000 | 99990000 | 101190000 | 100564000 |
Income Statement Trend
Dolby Laboratories Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 482.0M | 745.4M | 620.1M | 1.2B | 1.1B |
Short-term Investments | 0 | 139.1M | 189.2M | 38.8M | 46.9M |
Accounts Receivable | 315.5M | 262.2M | 243.6M | 232.6M | 180.3M |
Inventory | 33.7M | 35.6M | 23.5M | 11.0M | 25.6M |
Other Current Assets | 40.2M | 26.3M | 23.2M | 32.8M | 35.1M |
Total Current Assets | 1.2B | 1.5B | 1.3B | 1.8B | 1.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 283.4M | 252.1M | 229.2M | 214.1M | 199.6M |
Goodwill | 1.5B | 984.2M | 842.6M | 804.3M | 826.3M |
Intangible Assets | 434.5M | 167.4M | 112.3M | 122.9M | 152.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 340.4M | 296.5M | 238.7M | 217.3M | 210.1M |
Total Non-Current Assets | 1.9B | 1.5B | 1.4B | 1.3B | 1.4B |
Total Assets | 3.1B | 3.0B | 2.7B | 3.1B | 2.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 17.4M | 20.9M | 14.2M | 17.8M | 12.6M |
Short-term Debt | 12.2M | 13.6M | 13.3M | 15.4M | 15.8M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 417.8M | 422.2M | 277.5M | 315.7M | 267.1M |
Non-Current Liabilities | |||||
Long-term Debt | 34.8M | 37.0M | 37.7M | 56.7M | 65.3M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 52.6M | 29.6M | 12.2M | 15.4M | 32.0M |
Total Non-Current Liabilities | 205.2M | 185.4M | 161.0M | 185.7M | 211.8M |
Total Liabilities | 623.0M | 607.6M | 438.5M | 501.5M | 478.9M |
Equity | |||||
Common Stock | 94.0K | 94.0K | 94.0K | 100.0K | 99.0K |
Retained Earnings | 2.5B | 2.4B | 2.3B | 2.6B | 2.4B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.5B | 2.4B | 2.3B | 2.6B | 2.4B |
Key Metrics | |||||
Total Debt | 47.0M | 50.6M | 50.9M | 72.1M | 81.1M |
Working Capital | 776.6M | 1.1B | 1.0B | 1.4B | 1.3B |
Balance Sheet Composition
Dolby Laboratories Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 264.3M | 201.6M | 183.9M | 317.8M | 231.6M |
Depreciation & Amortization | 87.3M | 95.5M | 103.6M | 112.8M | 111.9M |
Stock-Based Compensation | 119.8M | 118.5M | 114.9M | 99.7M | 86.6M |
Working Capital Changes | -82.1M | 6.4M | -31.5M | -41.8M | -94.7M |
Operating Cash Flow | 356.9M | 401.0M | 336.5M | 446.0M | 341.0M |
Investing Activities | |||||
Capital Expenditures | -30.0M | -30.3M | -47.9M | -54.5M | -66.3M |
Acquisitions | -487.9M | 25.7M | -38.2M | -4.5M | 0 |
Investment Purchases | -160.2M | -173.0M | -316.3M | -67.1M | -287.8M |
Investment Sales | 391.8M | 231.8M | 118.0M | 64.8M | 491.1M |
Investing Cash Flow | -286.3M | 54.2M | -284.4M | -44.9M | 137.0M |
Financing Activities | |||||
Share Repurchases | -199.1M | -180.4M | -566.9M | -278.1M | -196.8M |
Dividends Paid | -114.6M | -103.4M | -100.1M | -89.2M | -88.6M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -287.8M | -236.8M | -610.6M | -252.5M | -207.8M |
Free Cash Flow | 297.2M | 336.7M | 259.1M | 393.3M | 274.9M |
Net Change in Cash | -217.2M | 218.4M | -558.5M | 148.6M | 270.3M |
Cash Flow Trend
Dolby Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.88
Forward P/E
19.12
Price to Book
2.68
Price to Sales
5.18
PEG Ratio
1.34
Profitability Ratios
Profit Margin
19.62%
Operating Margin
14.92%
Return on Equity
10.50%
Return on Assets
5.86%
Financial Health
Current Ratio
3.44
Debt to Equity
1.50
Beta
0.90
Per Share Data
EPS (TTM)
$2.71
Book Value per Share
$27.19
Revenue per Share
$14.06
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
dlb | 7.0B | 26.88 | 2.68 | 10.50% | 19.62% | 1.50 |
Cintas | 86.9B | 48.89 | 18.54 | 40.27% | 17.53% | 56.67 |
Copart | 46.1B | 31.58 | 5.25 | 18.44% | 32.21% | 1.15 |
Amentum Holdings | 6.1B | 118.76 | 1.36 | 1.80% | 0.41% | 97.71 |
Maximus | 4.8B | 15.75 | 2.69 | 17.61% | 5.83% | 100.48 |
Azz | 3.4B | 12.66 | 2.76 | 23.85% | 16.40% | 49.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.